These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7573097)

  • 1. Interferon-alpha therapy for chronic myelogenous leukemia.
    Wetzler M; Kantarjian H; Kurzrock R; Talpaz M
    Am J Med; 1995 Oct; 99(4):402-11. PubMed ID: 7573097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
    Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
    Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):8-13. PubMed ID: 7992099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
    Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A
    J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Steegmann JL; Casado LF; Tomás JF; Sanz-Rodríguez C; Granados E; de la Cámara R; Alegre A; Vázquez L; Ferro MT; Figuera A; Arranz R; Fernández-Rañada JM
    Bone Marrow Transplant; 1999 Mar; 23(5):483-8. PubMed ID: 10100563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress with interferon in CML--results of the MRC UK CML III study.
    Shepherd PC; Richards SM; Allan NC
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
    Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of interferon alfa-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation.
    Higano CS; Raskind WH; Singer JW
    Acta Haematol; 1993; 89 Suppl 1():8-14. PubMed ID: 8475671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.